{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T19:34:09Z","timestamp":1793475249750,"version":"4.5.0"},"reference-count":48,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T00:00:00Z","timestamp":1741305600000},"content-version":"unspecified","delay-in-days":65,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007687","name":"Svenska L\u00e4kares\u00e4llskapet","doi-asserted-by":"publisher","award":["SLS-974449"],"award-info":[{"award-number":["SLS-974449"]}],"id":[{"id":"10.13039\/501100007687","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006129","name":"Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse","doi-asserted-by":"publisher","award":["2022"],"award-info":[{"award-number":["2022"]}],"id":[{"id":"10.13039\/501100006129","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Region Stockholm","award":["FoUI-00436"],"award-info":[{"award-number":["FoUI-00436"]}]},{"DOI":"10.13039\/501100007857","name":"Stiftelsen Konung Gustaf V:s 80-\u00e5rsfond","doi-asserted-by":"publisher","award":["FAI-2022-0877"],"award-info":[{"award-number":["FAI-2022-0877"]}],"id":[{"id":"10.13039\/501100007857","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007857","name":"Stiftelsen Konung Gustaf V:s 80-\u00e5rsfond","doi-asserted-by":"publisher","award":["FAI-2023-1055"],"award-info":[{"award-number":["FAI-2023-1055"]}],"id":[{"id":"10.13039\/501100007857","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007949","name":"Reumatikerf\u00f6rbundet","doi-asserted-by":"publisher","award":["R-993724"],"award-info":[{"award-number":["R-993724"]}],"id":[{"id":"10.13039\/501100007949","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007949","name":"Reumatikerf\u00f6rbundet","doi-asserted-by":"publisher","award":["R-995882"],"award-info":[{"award-number":["R-995882"]}],"id":[{"id":"10.13039\/501100007949","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009800","name":"Stiftelsen Professor Nanna Svartz Fond","doi-asserted-by":"publisher","award":["2021-00436"],"award-info":[{"award-number":["2021-00436"]}],"id":[{"id":"10.13039\/501100009800","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Stiftelsen Ulla och Roland Gustafssons Donationsfond","award":["2023-36"],"award-info":[{"award-number":["2023-36"]}]},{"name":"Stiftelsen Ulla och Roland Gustafssons Donationsfond","award":["2024-43"],"award-info":[{"award-number":["2024-43"]}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["2023-02256"],"award-info":[{"award-number":["2023-02256"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004047","name":"Karolinska Institutet","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100023670","name":"Nyckelfonden","doi-asserted-by":"publisher","award":["OLL-1000881"],"award-info":[{"award-number":["OLL-1000881"]}],"id":[{"id":"10.13039\/501100023670","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2025,2,19]]},"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:p>Despite advancements in the management of systemic lupus erythematosus (SLE), patients experience poor health-related quality of life (hrQoL) and premature death due to disease severity and treatment side effects. Achieving remission offers substantial benefits, including improved hrQoL and reduced mortality, yet the complexity of SLE, with its diverse underlying immune mechanisms and clinical manifestations, hampers progress. Involvement of the central nervous system with symptoms like fatigue, pain and brain fog often goes unaddressed due to limited evidence-based guidance and measurement tools. This neglect reflects gaps in training, discomfort in addressing untreatable symptoms and an overemphasis on evidence-based medicine, compromising holistic care. Recognising patient-reported outcomes has shifted SLE care towards a more patient-centred model, addressing hrQoL and aligning treatment goals. Embracing this approach and prioritising symptom management, even when a definitive cure is lacking, ensures compassionate, comprehensive care that improves adherence, satisfaction and the overall lived experience of patients with SLE.<\/jats:p>","DOI":"10.1136\/rmdopen-2024-005400","type":"journal-article","created":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T13:41:05Z","timestamp":1741354865000},"page":"e005400","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":8,"title":["Holistic approaches in systemic lupus erythematosus: do physicians avoid addressing difficult-to-treat but highly relevant symptoms?"],"prefix":"10.1136","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4875-5395","authenticated-orcid":false,"given":"Ioannis","family":"Parodis","sequence":"first","affiliation":[{"name":"Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital, and Center for Molecular Medicine (CMM), Stockholm, Sweden"},{"name":"Department of Rheumatology, Faculty of Medicine and Health, \u00d6rebro University, \u00d6rebro, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8742-8311","authenticated-orcid":false,"given":"Chris","family":"Wincup","sequence":"additional","affiliation":[{"name":"Department of Clinical and Academic Rheumatology, King\u2019s College Hospital, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5177-2076","authenticated-orcid":false,"given":"Zahi","family":"Touma","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Toronto Lupus Program, University Health Network, Schroeder Arthritis Institute, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8848-9039","authenticated-orcid":false,"given":"Jeanette","family":"Andersen","sequence":"additional","affiliation":[{"name":"Lupus Europe, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4978-4072","authenticated-orcid":false,"given":"Vibeke","family":"Strand","sequence":"additional","affiliation":[{"name":"Division of Immunology\/Rheumatology, Stanford University, Stanford, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0900-2048","authenticated-orcid":false,"given":"Christopher","family":"Sj\u00f6wall","sequence":"additional","affiliation":[{"name":"Department of Biomedical and Clinical Sciences, Division of Inflammation and Infection\/Rheumatology, Link\u00f6ping University, Link\u00f6ping, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,3,7]]},"reference":[{"key":"2025090312060218000_11.1.e005400.1","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-020-02334-5","article-title":"Articular involvement, steroid treatment and fibromyalgia are the main determinants of patient-physician discordance in systemic lupus erythematosus","volume":"22","author":"Elefante","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"2025090312060218000_11.1.e005400.2","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2021.651249","article-title":"Adverse Health-Related Quality of Life Outcome Despite Adequate Clinical Response to Treatment in Systemic Lupus Erythematosus","volume":"8","author":"Gomez","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"2025090312060218000_11.1.e005400.3","doi-asserted-by":"publisher","DOI":"10.1002\/art.21955"},{"key":"2025090312060218000_11.1.e005400.4","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1002\/acr.20683","article-title":"Systematic review of the epidemiology of systemic lupus erythematosus in the Asia-Pacific region: prevalence, incidence, clinical features, and mortality","volume":"64","author":"Jakes","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025090312060218000_11.1.e005400.5","doi-asserted-by":"publisher","DOI":"10.1097\/01.md.0000170022.44998.d1"},{"key":"2025090312060218000_11.1.e005400.6","first-page":"848","article-title":"Survival analysis and prognostic indicators of systemic lupus erythematosus in Pakistani patients","volume":"18","author":"Rabbani","year":"2009","journal-title":"Lupus (Los Angel)"},{"key":"2025090312060218000_11.1.e005400.7","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1007\/s10067-014-2596-0","article-title":"Survival rates and risk factors for mortality in systemic lupus erythematosus patients in a Chinese center","volume":"33","author":"Wu","year":"2014","journal-title":"Clin Rheumatol"},{"key":"2025090312060218000_11.1.e005400.8","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223357"},{"key":"2025090312060218000_11.1.e005400.9","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-224762"},{"key":"2025090312060218000_11.1.e005400.10","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1136\/ard-2022-222487","article-title":"Remission and low disease activity (LDA) prevent damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort","volume":"81","author":"Ugarte-Gil","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"2025090312060218000_11.1.e005400.11","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2021-000542","article-title":"Achieving remission or low disease activity is associated with better outcomes in patients with systemic lupus erythematosus: a systematic literature review","volume":"8","author":"Ugarte-Gil","year":"2021","journal-title":"Lupus Sci Med"},{"key":"2025090312060218000_11.1.e005400.12","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keac185"},{"key":"2025090312060218000_11.1.e005400.13","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-224795"},{"key":"2025090312060218000_11.1.e005400.14","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(24)00398-2"},{"key":"2025090312060218000_11.1.e005400.15","doi-asserted-by":"crossref","first-page":"103025","DOI":"10.1016\/j.jaut.2023.103025","article-title":"Distinct gene dysregulation patterns herald precision medicine potentiality in systemic lupus erythematosus","volume":"136","author":"Lindblom","year":"2023","journal-title":"J Autoimmun"},{"key":"2025090312060218000_11.1.e005400.16","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1257085","article-title":"Serum profiling identifies CCL8, CXCL13, and IL-1RA as markers of active disease in patients with systemic lupus erythematosus","volume":"14","author":"Lindblom","year":"2023","journal-title":"Front Immunol"},{"key":"2025090312060218000_11.1.e005400.17","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-55833-9","article-title":"A case-control study on health-related quality of life of systemic lupus erythematosus patients","volume":"14","author":"Refai","year":"2024","journal-title":"Sci Rep"},{"key":"2025090312060218000_11.1.e005400.18","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/94.1.39"},{"key":"2025090312060218000_11.1.e005400.19","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1002\/acr.23509","article-title":"Cerebrovascular Events in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study","volume":"70","author":"Hanly","year":"2018","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025090312060218000_11.1.e005400.20","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1002\/art.40764","article-title":"Psychosis in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study","volume":"71","author":"Hanly","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2025090312060218000_11.1.e005400.21","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1002\/art.39111","article-title":"Mood Disorders in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study","volume":"67","author":"Hanly","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"2025090312060218000_11.1.e005400.22","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-216150"},{"key":"2025090312060218000_11.1.e005400.23","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-201089"},{"key":"2025090312060218000_11.1.e005400.24","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1007\/s00296-024-05667-5","article-title":"Neuropsychiatric involvement in systemic lupus erythematosus contributes to organ damage beyond the nervous system: a post-hoc analysis of 5 phase III randomized clinical trials","volume":"44","author":"Nikolopoulos","year":"2024","journal-title":"Rheumatol Int"},{"key":"2025090312060218000_11.1.e005400.25","doi-asserted-by":"crossref","first-page":"2494","DOI":"10.1093\/rheumatology\/keae216","article-title":"Patients with NPSLE experience poorer HRQoL and more fatigue than SLE patients with no neuropsychiatric involvement, irrespective of neuropsychiatric activity","volume":"63","author":"Nikolopoulos","year":"2024","journal-title":"Rheumatology (Oxford)"},{"key":"2025090312060218000_11.1.e005400.26","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keac002"},{"key":"2025090312060218000_11.1.e005400.27","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1093\/rheumatology\/keae120","article-title":"Lupus Low Disease Activity State and organ damage in relation to quality of life in systemic lupus erythematosus: a cohort study with up to 11 years of follow-up","volume":"64","author":"Parodis","year":"2025","journal-title":"Rheumatology (Oxford)"},{"key":"2025090312060218000_11.1.e005400.28","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2020-000469","article-title":"Living with systemic lupus erythematosus in 2020: a European patient survey","volume":"8","author":"Cornet","year":"2021","journal-title":"Lupus Sci Med"},{"key":"2025090312060218000_11.1.e005400.29","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10163566","article-title":"Fatigue in Systemic Lupus Erythematosus and Rheumatoid Arthritis: A Comparison of Mechanisms, Measures and Management","volume":"10","author":"Dey","year":"2021","journal-title":"J Clin Med"},{"key":"2025090312060218000_11.1.e005400.30","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11185300","article-title":"Fighting Fatigue in Systemic Lupus Erythematosus: Experience of Dehydroepiandrosterone on Clinical Parameters and Patient-Reported Outcomes","volume":"11","author":"Skoglund","year":"2022","journal-title":"J Clin Med"},{"key":"2025090312060218000_11.1.e005400.31","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s00296-024-05548-x","article-title":"Efficacy of lifestyle interventions in the management of systemic lupus erythematosus: a systematic review of the literature","volume":"44","author":"Tsoi","year":"2024","journal-title":"Rheumatol Int"},{"key":"2025090312060218000_11.1.e005400.32","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003297","article-title":"Systematic literature review informing the EULAR recommendations for the non-pharmacological management of systemic lupus erythematosus and systemic sclerosis","volume":"9","author":"Parodis","year":"2023","journal-title":"RMD Open"},{"key":"2025090312060218000_11.1.e005400.33","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-224416"},{"key":"2025090312060218000_11.1.e005400.34","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1080\/08916934.2018.1514496","article-title":"Active NET formation in Libman-Sacks endocarditis without antiphospholipid antibodies: A dramatic onset of systemic lupus erythematosus","volume":"51","author":"Appelgren","year":"2018","journal-title":"Autoimmunity"},{"key":"2025090312060218000_11.1.e005400.35","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1007\/s00296-023-05363-w","article-title":"Refractory systemic lupus erythematosus with chylous effusion successfully treated with sirolimus: a case report and literature review","volume":"43","author":"Banic","year":"2023","journal-title":"Rheumatol Int"},{"key":"2025090312060218000_11.1.e005400.36","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1093\/rheumatology\/kead689","article-title":"Lupus enteritis: a narrative review","volume":"63","author":"Mu\u00f1oz-Urbano","year":"2024","journal-title":"Rheumatology (Oxford)"},{"key":"2025090312060218000_11.1.e005400.37","doi-asserted-by":"crossref","first-page":"3471","DOI":"10.1093\/rheumatology\/kead685","article-title":"Attribution of neuropsychiatric symptoms and prioritization of evidence in the diagnosis of neuropsychiatric lupus: mixed methods analysis of patient and clinician perspectives from the international INSPIRE study","volume":"63","author":"Sloan","year":"2024","journal-title":"Rheumatology (Oxford)"},{"key":"2025090312060218000_11.1.e005400.38","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11020340","article-title":"Patient-Reported Outcomes in Systemic Lupus Erythematosus. Can Lupus Patients Take the Driver\u2019s Seat in Their Disease Monitoring?","volume":"11","author":"Parodis","year":"2022","journal-title":"J Clin Med"},{"key":"2025090312060218000_11.1.e005400.39","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2019-000373","article-title":"Measurement properties of selected patient-reported outcome measures for use in randomised controlled trials in patients with systemic lupus erythematosus: a systematic review","volume":"7","author":"Strand","year":"2020","journal-title":"Lupus Sci Med"},{"key":"2025090312060218000_11.1.e005400.40","doi-asserted-by":"crossref","first-page":"4703","DOI":"10.1093\/rheumatology\/keab080","article-title":"EQ-5D-3L full health state discriminates between drug and placebo in clinical trials of systemic lupus erythematosus","volume":"60","author":"Lindblom","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"2025090312060218000_11.1.e005400.41","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2022.1092325","article-title":"EQ-5D full health state after therapy heralds reduced hazard to accrue subsequent organ damage in systemic lupus erythematosus","volume":"9","author":"Lindblom","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"2025090312060218000_11.1.e005400.42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/PROM.S369584","article-title":"Impact of Belimumab on Patient-Reported Outcomes in Systemic Lupus Erythematosus: Insights from Clinical Trials and Real-World Evidence","volume":"14","author":"Gomez","year":"2023","journal-title":"Patient Relat Outcome Meas"},{"key":"2025090312060218000_11.1.e005400.43","doi-asserted-by":"crossref","first-page":"103188","DOI":"10.1016\/j.autrev.2022.103188","article-title":"Do biological agents improve health-related quality of life in patients with systemic lupus erythematosus? Results from a systematic search of the literature","volume":"21","author":"Gomez","year":"2022","journal-title":"Autoimmun Rev"},{"key":"2025090312060218000_11.1.e005400.44","doi-asserted-by":"crossref","first-page":"e198","DOI":"10.1016\/S2665-9913(21)00387-8","article-title":"Clinical meaningfulness of a British Isles Lupus Assessment Group-based Composite Lupus Assessment response in terms of patient-reported outcomes in moderate to severe systemic lupus erythematosus: a post-hoc analysis of the phase 3 TULIP-1 and TULIP-2 trials of anifrolumab","volume":"4","author":"Strand","year":"2022","journal-title":"Lancet Rheumatol"},{"key":"2025090312060218000_11.1.e005400.45","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1002\/acr.23788","article-title":"Long-Term Impact of Belimumab on Health-Related Quality of Life and Fatigue in Patients With Systemic Lupus Erythematosus: Six Years of Treatment","volume":"71","author":"Strand","year":"2019","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025090312060218000_11.1.e005400.46","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202865"},{"key":"2025090312060218000_11.1.e005400.47","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.022624"},{"key":"2025090312060218000_11.1.e005400.48","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11071857","article-title":"How Can We Enhance Adherence to Medications in Patients with Systemic Lupus Erythematosus? Results from a Qualitative Study","volume":"11","author":"Emamikia","year":"2022","journal-title":"J Clin Med"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2024-005400","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T19:06:15Z","timestamp":1756926375000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2024-005400"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,3,7]]},"published-print":{"date-parts":[[2025,1]]}},"alternative-id":["10.1136\/rmdopen-2024-005400"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2024-005400","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1]]}}}